Does the Diagnosis Center Influence the Prognosis of Ovarian Cancer Patients Submitted to Neoadjuvant Chemotherapy?

Giuseppe Vizzielli, Francesco Fanfani, Vito Chiantera, Lucia Tortorella, Alessandro Lucidi, Marco Petrillo, Barbara Costantini, Giovanni Scambia, Anna Fagotti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed. Patients and Methods: Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred-Interval Debulking Surgery)). Results: Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS. Median progression-free survival (PFS) was 26 months in PDS, 14 months in I-IDS and 17 months in R-IDS. The difference was statistically significant (p<0.05) among all groups. Conclusion: IDS can represent a suitable approach only when the first complete debulking is not achievable in a tertiary referral hospital.
Original languageEnglish
Pages (from-to)3027-3032
Number of pages6
JournalAnticancer Research
Volume35
Publication statusPublished - 2015

Keywords

  • neoadjuvant chemotherapy
  • ovarian cancer

Fingerprint

Dive into the research topics of 'Does the Diagnosis Center Influence the Prognosis of Ovarian Cancer Patients Submitted to Neoadjuvant Chemotherapy?'. Together they form a unique fingerprint.

Cite this